Indication
As monotherapy for the treatment of adult patients with advanced human-epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
Medicine details
- Medicine name:
- trastuzumab deruxtecan (Enhertu)
- SMC ID:
- SMC3000
- Pharmaceutical company
- Daiichi Sankyo UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC